For PD-L1 CPS ≥ 1 tumor, the median PFS in pembrolizumab and paclitaxel groups were 1.5 months (95% CI 1.4–2.0) and 4.1 months (95% CI 3.1–4.2), respectively (HR 1.27, 95% CI 1.03–1.57). This evidence concerns the gene CD274 and neoplasm.